Your browser doesn't support javascript.
loading
STAT3 is over-activated within CD163pos bone marrow macrophages in both Multiple Myeloma and the benign pre-condition MGUS.
Andersen, Morten N; Andersen, Niels F; Lauridsen, Kristina L; Etzerodt, Anders; Sorensen, Boe S; Abildgaard, Niels; Plesner, Trine; Hokland, Marianne; Møller, Holger J.
Affiliation
  • Andersen MN; Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark. morten@biomed.au.dk.
  • Andersen NF; Department of Biomedicine, Aarhus University, Aarhus, Denmark. morten@biomed.au.dk.
  • Lauridsen KL; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark. morten@biomed.au.dk.
  • Etzerodt A; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.
  • Sorensen BS; Department of Histopathology, Aarhus University Hospital, Aarhus, Denmark.
  • Abildgaard N; Department of Biomedicine, Aarhus University, Aarhus, Denmark.
  • Plesner T; Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.
  • Hokland M; Department of Hematology, Odense University Hospital, Odense, Denmark.
  • Møller HJ; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Cancer Immunol Immunother ; 71(1): 177-187, 2022 Jan.
Article in En | MEDLINE | ID: mdl-34061243
ABSTRACT
Tumour-associated macrophages (TAMs) support cancer cell survival and suppress anti-tumour immunity. Tumour infiltration by CD163pos TAMs is associated with poor outcome in several human malignancies, including multiple myeloma (MM). Signal transducer and activator of transcription 3 (STAT3) is over-activated in human cancers, and specifically within TAMs activation of STAT3 may induce an immunosuppressive (M2-like) phenotype. Therefore, STAT3-inhibition in TAMs may be a future therapeutic strategy.We investigated TAM markers CD163, CD206, and activated STAT3 (pSTAT3) in patients with MGUS (n = 32) and MM (n = 45), as well as healthy controls (HCs, n = 13).Blood levels of the macrophage biomarkers sCD163 and sCD206, and circulating cytokines, as well as bone marrow mRNA expression of CD163 and CD206, were generally increased in MGUS and MM patients, compared to HCs, but to highly similar levels. By immunohistochemistry, bone marrow levels of pSTAT3 were increased specifically within CD163pos cells in both MGUS and MM patients.In conclusion, macrophage-related inflammatory changes, including activation of STAT3, were present already at the MGUS stage, at similar levels as in MM. Specific increase in pSTAT3 levels within CD163pos cells supports that the CD163 scavenger receptor may be a useful target for future delivery of STAT3-inhibitory drugs to TAMs in MM patients.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bone Marrow / Monoclonal Gammopathy of Undetermined Significance / Antigens, Differentiation, Myelomonocytic / Antigens, CD / Receptors, Cell Surface / STAT3 Transcription Factor / Macrophages / Multiple Myeloma Type of study: Observational_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Cancer Immunol Immunother Journal subject: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Year: 2022 Document type: Article Affiliation country: Dinamarca

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bone Marrow / Monoclonal Gammopathy of Undetermined Significance / Antigens, Differentiation, Myelomonocytic / Antigens, CD / Receptors, Cell Surface / STAT3 Transcription Factor / Macrophages / Multiple Myeloma Type of study: Observational_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Cancer Immunol Immunother Journal subject: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Year: 2022 Document type: Article Affiliation country: Dinamarca